Trial Profile
GSK - Doublet: A Phase I Study of Pegylated Liposomal Doxorubicin (Doxil) and Weekly Intravenous Topotecan in Patients With Advanced Solid Tumors
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 22 Aug 2023
Price :
$35
*
At a glance
- Drugs Doxorubicin liposomal (Primary) ; Topotecan (Primary)
- Indications Solid tumours
- Focus Therapeutic Use
- 16 May 2006 Status changed from recruiting to completed.
- 22 Dec 2005 New trial record.